Radioembolization for hepatocellular carcinoma with portal vein thrombosis: impact of liver function on systemic treatment options at disease progression.

[1]  A. Benson,et al.  Extrahepatic metastases occur in a minority of hepatocellular carcinoma patients treated with locoregional therapies: Analyzing patterns of progression in 285 patients , 2012, Hepatology.

[2]  F. Izzo,et al.  Survival after yttrium‐90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation , 2011, Hepatology.

[3]  A. Benson,et al.  Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation. , 2011, Journal of hepatology.

[4]  J. Bruix,et al.  Management of hepatocellular carcinoma: An update , 2011, Hepatology.

[5]  D. Sze,et al.  Research reporting standards for radioembolization of hepatic malignancies. , 2011, Journal of vascular and interventional radiology : JVIR.

[6]  A. Benson,et al.  Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[7]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[8]  A. Benson,et al.  Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma. , 2010, JAMA.

[9]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[10]  A. Benson,et al.  Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. , 2010, Gastroenterology.

[11]  M. Abecassis,et al.  A Comparative Analysis of Transarterial Downstaging for Hepatocellular Carcinoma: Chemoembolization Versus Radioembolization , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  Jordi Rimola,et al.  Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma , 2009, Cancer.

[13]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[14]  S. Paggi,et al.  Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .

[15]  J. Bruix,et al.  Molecular targeted therapies in hepatocellular carcinoma , 2008, Hepatology.

[16]  A. Benson,et al.  Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis , 2007, Hepatology.

[17]  Riccardo Lencioni,et al.  Design and endpoints of clinical trials in hepatocellular carcinoma. , 2008, Journal of the National Cancer Institute.

[18]  J. Prieto,et al.  Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. , 2006, International journal of radiation oncology, biology, physics.

[19]  Kenneth G. Thurston,et al.  Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. , 2006, Journal of vascular and interventional radiology : JVIR.

[20]  Kenneth G. Thurston,et al.  Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. , 2005, Journal of vascular and interventional radiology : JVIR.

[21]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[22]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[23]  M. Soulen,et al.  Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. , 2004, Gastroenterology.

[24]  L Pagliaro,et al.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. , 2001, Journal of hepatology.

[25]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[26]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[27]  B. Davidson,et al.  Incidence, risk factors, management, and outcome of portal vein abnormalities at orthotopic liver transplantation. , 1994, Transplantation.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .